Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
about
Candida glabrata persistence in mice does not depend on host immunosuppression and is unaffected by fungal amino acid auxotrophy.Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infectionsDevelopment of amphotericin B-loaded cubosomes through the SolEmuls technology for enhancing the oral bioavailability.Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem celPulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations.Tissue penetration of antifungal agents.Central nervous system toxicity associated with liposomal amphotericin B therapy for cutaneous leishmaniasis.Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.Synergistic enhancement of parasiticidal activity of amphotericin B using copaiba oil in nanoemulsified carrier for oral delivery: an approach for non-toxic chemotherapySelf assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasis.Virulence and Resistance to Antifungal Therapies of Scopulariopsis Species.Biodistribution and In Vivo Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl-sn-Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B.Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens.Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis.Suspected Pulmonary Infection with Trichoderma longibrachiatum after Allogeneic Stem Cell Transplantation.New Insights Regarding Yeast Survival following Exposure to Liposomal Amphotericin B.Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition.Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats.Successful stepdown treatment of pulmonary histoplasmosis with thrice-weekly liposomal amphotericin B in a hospital-associated, outpatient infusion centre: A case report.A Young, Immunocompetent Woman with Small Bowel and Hepatic Mucormycosis Successfully Treated with Aggressive Surgical Debridements and Antifungal Therapy.The Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles.
P2860
Q33675986-67EC3D07-F725-4186-AE9A-5D54E977B4BAQ34108585-873814F3-C01F-46DE-94C3-BC2FF899CAEBQ36442187-565BC36C-A0D6-4F20-916F-64D3C5AA95D4Q36868273-E412B63E-95DD-44FD-885F-C1D1B5FA12ABQ37026715-6635DB69-18A8-44F2-973A-323CE4F87F31Q37333175-A599533A-97F8-4C61-873A-82F660E0C73AQ37409856-F7A9401B-1EF8-45AD-B430-8913EEED10DCQ37544911-09BCE67A-A55D-4778-A1F8-B203437B26ACQ37860768-2D92626D-2437-458E-B262-E87A41A87118Q38653256-F98C9A35-37ED-4745-974C-50EE2532A833Q38892819-B65F5971-1F52-45B3-861E-6C0E8F7DDDE2Q38937745-41B3D91D-1ED0-423A-BE83-8BE3EEDF1F8DQ39515584-4755F56F-0D54-4883-A414-A18C76117B89Q40166247-F55BB238-9B32-44F9-8E19-7F5457F25E9FQ40222438-DE498532-50F3-496B-B128-D23602E19C51Q40287344-DEBCD260-1A73-4494-96A5-CEDE8EE11617Q40370989-AB383D1F-462A-4238-B44C-D2724CA1D3E8Q41066158-AF33BA96-25D9-46AD-BBB4-553785112757Q42217419-5E17ED62-63B0-4DC2-8EE7-1821B1F016BCQ44786792-6F8FD748-051D-46E2-949A-D42DFCDC0CABQ45850524-45ED0F78-0283-4817-B439-7668AB04E925Q48243384-5FCAC5E8-BBE6-4EEB-AC27-88118377522BQ49515324-06D59494-826B-4097-8987-589E98CF28A4Q50043447-6F4A8BA5-43DB-4832-AB67-2B9A93424C2A
P2860
Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Effects of dosing regimen on a ...... y of liposomal amphotericin B.
@en
Effects of dosing regimen on a ...... y of liposomal amphotericin B.
@nl
type
label
Effects of dosing regimen on a ...... y of liposomal amphotericin B.
@en
Effects of dosing regimen on a ...... y of liposomal amphotericin B.
@nl
prefLabel
Effects of dosing regimen on a ...... y of liposomal amphotericin B.
@en
Effects of dosing regimen on a ...... y of liposomal amphotericin B.
@nl
P2093
P2860
P356
P1476
Effects of dosing regimen on a ...... y of liposomal amphotericin B.
@en
P2093
David Constable
Jill P Adler-Moore
Jon A Olson
Julie Schwartz
Peter J Smith
Richard T Proffitt
P2860
P304
P356
10.1093/JAC/DKM077
P407
P577
2007-03-30T00:00:00Z